What is Independent and Community Pharmacy's cybersecurity risk score?

Independent and Community Pharmacy has an AI-generated cybersecurity risk score of 749 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has Independent and Community Pharmacy experienced?

According to Rankiteo, Independent and Community Pharmacy currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Independent and Community Pharmacy been affected by any supply chain cyber incidents ?

According to Rankiteo, Independent and Community Pharmacy has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Independent and Community Pharmacy have SOC 2 Type 1 certification ?

According to Rankiteo, Independent and Community Pharmacy is not certified under SOC 2 Type 1.

Does Independent and Community Pharmacy have SOC 2 Type 2 certification ?

According to Rankiteo, Independent and Community Pharmacy does not hold a SOC 2 Type 2 certification.

Does Independent and Community Pharmacy comply with GDPR ?

According to Rankiteo, Independent and Community Pharmacy is not listed as GDPR compliant.

Does Independent and Community Pharmacy have PCI DSS certification ?

According to Rankiteo, Independent and Community Pharmacy does not currently maintain PCI DSS compliance.

Does Independent and Community Pharmacy comply with HIPAA ?

According to Rankiteo, Independent and Community Pharmacy is not compliant with HIPAA regulations.

Does Independent and Community Pharmacy have ISO 27001 certification ?

According to Rankiteo,Independent and Community Pharmacy is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Independent and Community Pharmacy operate in ?

Independent and Community Pharmacy operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Independent and Community Pharmacy have ?

Independent and Community Pharmacy employs approximately 5 people worldwide.

Does Independent and Community Pharmacy own any subsidiaries ?

Independent and Community Pharmacy presently has no subsidiaries across any sectors.

How many LinkedIn followers does Independent and Community Pharmacy have ?

Independent and Community Pharmacy's official LinkedIn profile has approximately 11,828 followers.

Does Independent and Community Pharmacy have a Crunchbase profile ?

No, Independent and Community Pharmacy does not have a profile on Crunchbase.

Does Independent and Community Pharmacy have a LinkedIn profile ?

Yes, Independent and Community Pharmacy maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/mckesson-retail-pharmacy.

How many cybersecurity incidents has Independent and Community Pharmacy experienced ?

As of June 16, 2026, Rankiteo reports that Independent and Community Pharmacy has not experienced any cybersecurity incidents.

How many peer or competitor companies does Independent and Community Pharmacy have ?

Independent and Community Pharmacy has an estimated 5,692 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

ICP

Boost Score +25 with badge (5 left)

749

/1000

Moderate

774

/1000

Fair

Independent and Community Pharmacy Vendor Cyber Rating & Cyber Score

https://ideashare-prd.azurewebsites.net/?utm_medium=social&utm_source=li&utm_campaign=2021+ideashare&utm_content=07272021&utm_term=profile

Add Your Compliance Badge

For Health Marts and other independent pharmacies, we host McKesson ideaShare - the leading conference designed to help independent pharmacy owners and their staff improve their knowledge, performance and profitability. Attend to share ideas, ask questions and gather recommendations while interacting with other community pharmacists, technicicans and pharmacy managers, McKesson leaders, industry experts and quality vendors. Join us in New Orleans in 2024, for focused learning, interactive exhibits, engaging workshops and meaningful conversations with peers. To learn more visit https://mckessonideashare.com/

ICP A.I CyberSecurity Scoring

Scoring History

ICP

Independent and Community Pharmacy CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

ICP Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for ICP

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Independent and Community Pharmacy in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Independent and Community Pharmacy in 2026.

Incident Types ICP vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Independent and Community Pharmacy in 2026.

Incident History - ICP (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Independent and Community Pharmacy Subsidiaries

ICP

Pharmaceutical Manufacturing

Website: https://ideashare-prd.azurewebsites.net/?utm_medium=social&utm_source=li&utm_campaign=2021+ideashare&utm_content=07272021&utm_term=profile

Company Size: 5

McKessonHospitals and Health Care

Independent and Community PharmacyRetail Pharmacies

Health Mart® CorporateRetail Pharmacies

Rx Savings SolutionsHospitals and Health Care

McKesson CompileTechnology, Information and Internet

Biologics by McKessonHospitals and Health Care

GenospaceData Infrastructure and Analytics

Loading…

Independent and Community Pharmacy Similar Companies

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Loading…

NEWS

Independent and Community Pharmacy CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Good Neighbor Pharmacy Celebrates Independent Community Pharmacy Excellence at ThoughtSpot 2025

Four-day conference underscores the vital role of independent pharmacies as accessible healthcare destinations, focusing on the "future of ...

Read Article

Empowering Independent Pharmacies with Health Mart

Empower your pharmacy with Health Mart's support for growth, clinical excellence, and community impact. Join us to thrive in today's marketplace.

Read Article

Clover Health Partners With 1000+ Local Pharmacies to Transform Medicare Care Delivery in New Jersey

Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on ...

Read Article

Change Healthcare data breach: Industry 'not fine' 1 year later

It's been one year since the unprecedented Change Healthcare cyberattack crippled hospitals, medical groups, payers and pharmacies.

Read Article

American Associated Pharmacies Struck by Ransomware Attack

The latest important healthcare entity to become the victim of a ransomware attack is American Associated Pharmacies (AAP). According to The ...

Read Article

7 Ways Pharmacies Can Grow Amid Challenges in 2025

Staffing shortages, rising costs and burnout demand automation. Pharmacy automation solutions can handle the operational burdens that drain ...

Read Article

Pharmacy closures pose risk for minority communities

A study analyzing trends in pharmacy closures found that closures exceeded pharmacy openings between 2018 and 2021, disproportionately impacting ...

Read Article

GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing

Community Link allows independent pharmacies to direct contract with GoodRx, manage participation in the company's Integrated Savings ...

Read Article

Cardinal Health Unveils Major Financial Initiative to Empower Independent Pharmacy Advocacy Nationwide

Cardinal Health (NYSE: CAH) has launched the Cardinal Health™ One Voice Initiative, a new program designed to provide financial support to state ...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-53430

SUMMARY

Improper Handling of Highly Compressed Data (Data Amplification) vulnerability in elixir-grpc grpc (GRPC.Compressor.Gzip, GRPC.Message modules) allows a denial of service via a gzip decompression bomb. This vulnerability is associated with program files lib/grpc/compressor/gzip.ex, lib/grpc/message.ex and program routines 'Elixir.GRPC.Compressor.Gzip':decompress/1, 'Elixir.GRPC.Message':from_data/2. 'Elixir.GRPC.Compressor.Gzip':decompress/1 calls :zlib.gunzip/1 directly on attacker-controlled bytes with no decompressed-size limit, ratio check, or incremental decoding. Because this module is the registered gzip GRPC.Compressor implementation, it is invoked automatically whenever an incoming gRPC frame carries the grpc-encoding: gzip header. :zlib.gunzip/1 allocates the entire decompressed result as a single binary, so a small highly compressible payload (for example a few kilobytes of zeros, which gzip compresses at roughly 1000:1) expands to multiple gigabytes inside a single call. The max_receive_message_length limit is enforced only against the already-decompressed message, so it provides no protection. An unauthenticated remote peer can send a single crafted frame to exhaust the BEAM node's heap and trigger an out-of-memory kill. This issue affects grpc: from 0.4.0 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-48854

SUMMARY

Allocation of Resources Without Limits or Throttling vulnerability in elixir-grpc grpc allows unauthenticated attackers to exhaust the BEAM's memory and crash the server by streaming a large or slow-trickle unary request body. 'Elixir.GRPC.Server.Adapters.Cowboy.Handler':read_full_body/3 (lib/grpc/server/adapters/cowboy/handler.ex) accumulates every received chunk into a single growing binary with no size cap. Additionally, when the client omits the grpc-timeout header, the per-chunk read timeout resolves to :infinity, allowing a slow-trickle client to keep the connection alive indefinitely while memory grows. A single connection is sufficient to exhaust server memory and crash the node. This issue affects grpc from 0.3.1 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-48853

SUMMARY

Deserialization of Untrusted Data and Allocation of Resources Without Limits or Throttling vulnerabilities in elixir-grpc grpc allow unauthenticated attackers to crash the BEAM node via atom table exhaustion and, when a decoded term flows into a call site that invokes it, achieve remote code execution on the server. 'Elixir.GRPC.Codec.Erlpack':decode/2 (lib/grpc/codec/erlpack.ex) calls :erlang.binary_to_term/1 on the raw gRPC message body without the :safe option, no size bound, and no type guard. Any unauthenticated peer that sends a request with Content-Type: application/grpc+erlpack can send a crafted payload that mints arbitrary new atoms (which are never garbage-collected, exhausting the bounded atom table and crashing the VM) or that encodes a fun term which, if applied anywhere downstream, executes attacker-controlled code inside the server process. This issue affects grpc from 0.4.0 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 9.2

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-48723

SUMMARY

The browserstack-cypress-cli is BrowserStack's CLI which allows users to run Cypress tests on BrowserStack. Versions prior to 1.36.4 are vulnerable to OS command injection via the cypress_config_file configuration parameter. In readCypressConfigUtil.js, the loadJsFile() function constructs a shell command by interpolating the user-controlled cypress_config_filepath value into a template literal, then executes it via child_process.execSync(). Shell metacharacters in the config path (specifically " and ;) allow breaking out of the quoted argument and injecting arbitrary commands. This issue has been fixed in version 1.36.6.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-48599

SUMMARY

Authorization Bypass Through User-Controlled Key vulnerability in elixir-grpc grpc allows authenticated attackers to access or modify resources belonging to other users by smuggling a conflicting value for any path-bound field via the query string or request body. In 'Elixir.GRPC.Server.Transcode':map_request/5 (lib/grpc/server/transcode.ex), all three clauses use Map.merge/2 with path bindings as the first argument, giving them the lowest merge precedence. A request such as GET /users/me/profile?user_id=victim (or a POST with {"user_id": "victim"} when body: "*") yields a decoded protobuf struct where the path-bound field carries the attacker-supplied value rather than the router-extracted value. Any handler that uses the path-bound field for authorization, multi-tenancy scoping, or ownership checks is silently bypassed. This issue affects grpc from 0.8.0 before 1.0.0.

Published

Date2026-06-15

Updated

Date2026-06-15

RISK INFORMATION (Score: )

cvss4

Base Score: 7.6

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…